Mirum Pharmaceuticals Inc (STU:08D)
€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Q2 2024 Mirum Pharmaceuticals Inc Earnings Call Transcript

Aug 07, 2024 / 08:30PM GMT
Release Date Price: €35.4 (-1.67%)
Operator

Thank you for your patience everyone. The Mirum Pharmaceutics report second quarter 2024 financial results and provide business update will begin shortly. (Operator Instructions)

Good afternoon, everyone and welcome to the Mirum Pharmaceutics report second quarter 2024 financial results and provide business update. My name is Carla and I will be coordinating your call today. (Operator Instructions) I will now hand you over to Andrew Mckibben, Vice President of Investor Relations and Finance to begin. Andrew, please go ahead.

Andrew Mckibben
Mirum Pharmaceuticals Inc - IR Contact Officer

Thanks, Carla and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals second quarter 2024 conference call. I'm joined today by our CEO, Chris Peetz; our President and Chief Operating Officer, Peter Radovich, our Chief Medical Officer, Joanne Quan; and Eric Bjerkholt, our Chief Financial Officer.

Earlier today, Mirum issued a news release announcing the company's results for the second quarter 2024. Copies of this news release and SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot